Boxlight CorporationPlacement Agent Agreement • February 21st, 2025 • Boxlight Corp • Services-educational services • New York
ContractPlacement Agent Agreement • April 20th, 2023 • Soligenix, Inc. • Pharmaceutical preparations • New York
Soligenix, Inc. Attention: Christopher J. Schaber, President and Chief Executive Officer 29 Emmons Drive, Suite B-10Princeton, NJ 08540
Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101Placement Agent Agreement • February 3rd, 2023 • Quoin Pharmaceuticals, Ltd. • Surgical & medical instruments & apparatus • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of not less than $10 million of registered securities of the Company, consisting of: (i) ordinary shares, no par value (the “Ordinary Shares”) represented by American Depositary Shares (the “ADSs”), with each ADS representing five thousand (5,000) Ordinary Shares, (ii) pre-funded warrants to purchase Ordinary Shares represented by ADSs (the “Pre-Funded Warrants”), and (iii) warrants to purchase ADSs (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrant
Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101Placement Agent Agreement • August 3rd, 2022 • Quoin Pharmaceuticals, Ltd. • Surgical & medical instruments & apparatus • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of no less than $12 million of registered securities of the Company, consisting of: (i) ordinary shares, no par value (the “Ordinary Shares”) represented by American Depositary Shares (the “ADSs”), with each ADS representing five thousand (5,000) Ordinary Shares, (ii) pre-funded warrants to purchase Ordinary Shares represented by ADSs (the “Pre-Funded Warrants”), and (iii) warrants to purchase ADSs (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants